Dr Morris Talks KRAS G12C Mutated CRC
Van Morris, MD, MD Anderson Cancer Center, discusses KRAS G12C mutated colorectal cancer at the 2022 GDU GI Meeting.
Transcript
And then I also talked a little bit about, in this talk, about KRAS G12C mutated CRC. In recent years, we've seen the advent of KRAS inhibitors, which are specific to G12C, which have shown some kind of early signal in patients with KRAS G12C non-small cell lung cancer and colorectal cancer. Response rates with single agents are in the 7% on the CodeBreak 100 study, 22% on the CRYSTAL 1 study. But very interesting kind of data which also came out of CRYSTAL 1, showing that the G12C inhibitor plus rituximab, an overall response rate that exceeded 40%. In future trials, we'll kind of look at this combination in more detail as well. So a lot that's interesting on the horizon. I think that the theme of that session was that even though you may have the same exact mutation in colorectal cancer as you see in other solid tumors, we don't see the same outcomes in colorectal cancer. And this really highlights the need for colorectal-cancer specific combination approaches.
Disclaimer: The views and opinions expressed are those of the author(s) and do not necessarily reflect the official policy or position of Oncology Learning Network or HMP Global, their employees, and affiliates. Any content provided by our bloggers or authors are of their opinion and are not intended to malign any religion, ethnic group, club, association, organization, company, individual, anyone, or anything.
